Typhoid Vi Polysaccharide Vaccine Market Report 2025

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $5.78 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $13.36 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors. Major trends in the forecast period include R&D investments, regulatory support, epidemiological studies, public health awareness.

The increasing prevalence of typhoid is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Typhoid is an infection caused by the bacteria Salmonella typhi, which can be life-threatening and is typically spread through contaminated food or drink. The Typhoid Vi polysaccharide vaccine is administered to immunize both adults and children aged two and older against typhoid fever caused by Salmonella enterica serovar Typhi (S. Typhi). For example, in August 2024, data published by the UK Health Security Agency, a government agency in the UK, revealed that laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland rose from 2021 to 2022, with cases of S. Typhi increasing from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the rising prevalence of typhoid is fueling the growth of the typhoid VI polysaccharide vaccine market.

The expansion of immunization campaigns is expected to drive the growth of the typhoid VI polysaccharide vaccine market in the coming years. Immunization campaigns are strategies designed to rapidly deliver one or more vaccines to large populations, typically organized at the national or sub-national level. These campaigns are crucial for the effective distribution and use of the typhoid VI polysaccharide vaccine, particularly in areas where typhoid fever presents a significant public health issue. For example, in April 2022, the Government of Nepal, with support from Gavi, the Vaccine Alliance - a public-private global health partnership - the World Health Organization (WHO), a Switzerland-based intergovernmental organization, and the United Nations International Children's Emergency Fund (UNICEF), a US-based humanitarian aid organization, launched a new vaccination campaign to incorporate the Typhoid Conjugate Vaccine (TCV) into the country's routine immunization program. This three-week campaign, running from April 8 to May 1, 2022, aims to vaccinate all children aged 15 months to 15 years to quickly enhance protection against typhoid, maximize the impact of the vaccine introduction, and address the growing issue of antimicrobial resistance. More than 50,000 vaccination sites have been set up across both rural and urban areas of the country, including schools. Thus, the increasing number of immunization campaigns is driving the growth of the typhoid VI polysaccharide vaccine market.

Increasing expenditure in the healthcare sector is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Healthcare expenditure encompasses the total costs associated with healthcare, including both public and private spending, as a percentage of GDP. Higher healthcare expenditure enables manufacturers of the typhoid VI polysaccharide vaccine to develop additional vaccines, thereby boosting demand in the market. For example, in September 2024, statistics released by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. Americans spent $576.9 billion on medications in 2021, with projected spending expected to rise to between $605 billion and $635 billion by 2025. Thus, the increasing expenditure in the healthcare sector is fueling the growth of the typhoid VI polysaccharide vaccine market.

Strategic partnerships are emerging as a significant trend in the typhoid VI polysaccharide vaccine market. Key players in this market are forming alliances to enhance their positions within the typhoid VI polysaccharide sector. For example, in July 2022, the International Vaccine Institute, an organization based in South Korea that focuses on infectious diseases of global health significance such as cholera, typhoid, shigella, and salmonella, collaborated with Moderna, a US-based biopharmaceutical firm. This partnership resulted in the development of the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Key companies in the typhoid VI polysaccharide vaccine market are prioritizing investments to maintain their competitive edge. Significant investments in the development and distribution of the typhoid VI polysaccharide vaccine highlight the critical importance of preventing and controlling typhoid fever. For instance, in August 2023, SK Bioscience, a South Korean biotech firm, and Vaxxas, an Australian biotechnology company specializing in a novel needle-free vaccination technology, secured AUD5.4 million (approximately $3.67 million) in funding from Wellcome, a UK-based charity. This funding aims to develop a typhoid conjugate vaccine that can be administered through a needle-free patch. This collaboration seeks to transform vaccine delivery by creating an innovative vaccine-delivery device that combines Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK Bioscience's proprietary typhoid vaccine.

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited.

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Typhoid Vi polysaccharide vaccine is recommended for active immunization in individuals aged two and older to prevent typhoid fever caused by Salmonella typhi.

The primary variants of this vaccine are tailored for pediatric and adult use. A child denotes an individual from birth to puberty or reaching full physical maturity. The vaccine can be administered orally or through parenteral routes and is accessible across governmental, private, and other institutional healthcare settings.

The typhoid Vi polysaccharide vaccine market research report is one of a series of new reports that provides typhoid Vi polysaccharide vaccine market statistics, including typhoid Vi polysaccharide vaccine industry global market size, regional shares, competitors with typhoid Vi polysaccharide vaccine market share, detailed typhoid Vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in typhoid Vi polysaccharide vaccine industry. This Typhoid Vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.